Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
J Clin Invest
    May 2026
  1. XING W, Zhou Y, Haedicke K, Wang C, et al
    Label-free streamlined photoacoustic image guidance facilitates NIR-II photoablation in models of melanoma lung metastases.
    J Clin Invest. 2026;136:e196095.
    >> Share

    April 2026
  2. ZHAO Y, Zhou Y, Pan L, Tian GG, et al
    Therapy-induced cholesterol biosynthesis drives lung cancer dormancy and drug resistance.
    J Clin Invest. 2026;136:e191735.
    >> Share

    March 2026
  3. ZHUANG WT, Pang LL, Hu LY, Liao J, et al
    EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-gamma.
    J Clin Invest. 2026;136:e194377.
    >> Share

    February 2026
  4. BURNS TF, Dacic S, Chakka A, Miller E, et al
    MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype.
    J Clin Invest. 2025;136:e194708.
    >> Share

  5. LI H, De Santis MC, Tucci FA, Tosoni D, et al
    SH3BP5L triggers the RAB11A-regulated integrin recycling network implicated in breast cancer metastasis.
    J Clin Invest. 2026;136:e192705.
    >> Share

  6. GHOSH M, Wu C, Kumar A, Nilsson M, et al
    Osimertinib activates a TGF-beta2-dependent secretory program that drives lung adenocarcinoma progression.
    J Clin Invest. 2025;136:e198418.
    >> Share

    January 2026
  7. KENT JR, Abbott KL, Nordgren R, Deik A, et al
    Intraoperative arteriovenous patient sampling to assess in situ non-small cell lung cancer metabolism.
    J Clin Invest. 2026 Jan 27:e198821. doi: 10.1172/JCI198821.
    >> Share

    December 2025
  8. QIU Z, Song NJ, Li A, Singh D, et al
    PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation.
    J Clin Invest. 2025 Dec 18:e193354. doi: 10.1172/JCI193354.
    >> Share

    November 2025
  9. HAJI S, Ogawa Y
    TET3-overexpressing macrophages are a unifying pathogenic feature with therapeutic potential in chronic inflammatory diseases.
    J Clin Invest. 2025;135:e198802.
    >> Share

  10. LIU B, Dai Y, Wang Z, Song J, et al
    TET3 is a common epigenetic immunomodulator of pathogenic macrophages.
    J Clin Invest. 2025;135:e194879.
    >> Share

    October 2025
  11. DRAGONI F, Sop J, Gurumurthy I, Beckey TP, et al
    Selective targeting of HIV infected clones by cognate peptide stimulation and antiproliferative drugs.
    J Clin Invest. 2025 Oct 21:e197266. doi: 10.1172/JCI197266.
    >> Share

  12. ZENG C, Wang X, Zhong J, Zhang Y, et al
    PIM3-mediated phosphorylation stabilizes myeloid leukemia factor 2 to promote metastasis in osteosarcoma.
    J Clin Invest. 2025;135:e191040.
    >> Share

  13. RAINES B, Tseng-Rogenski S, Dowdican AC, Peris I, et al
    A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell lung cancer.
    J Clin Invest. 2025 Oct 14:e193790. doi: 10.1172/JCI193790.
    >> Share

    September 2025
  14. KRATZMEIER C, Taheri M, Mei Z, Lim I, et al
    Lung adenocarcinoma-derived IFN-gamma promotes growth by modulating CD8+ T cell production of CCR5 chemokines.
    J Clin Invest. 2025;135:e191070.
    >> Share

    August 2025
  15. XIONG T, Wang G, Yu P, Li Z, et al
    CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors.
    J Clin Invest. 2025;135:e189920.
    >> Share

    July 2025
  16. KIM YS, Nabet BY, Cortez BN, Sun NY, et al
    NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING.
    J Clin Invest. 2025 Jul 8:e185423. doi: 10.1172/JCI185423.
    >> Share

    June 2025
  17. DESAI SS, Salahuddin S, Yusuf R, Ranjan K, et al
    Tumor microenvironment of non-small cell lung cancer impairs immune cell function among people with HIV.
    J Clin Invest. 2025 Jun 3:e177310. doi: 10.1172/JCI177310.
    >> Share

  18. LEE S, Park J, Cho S, Kim EJ, et al
    Hyaluronan network remodeling by ZEB1 and ITIH2 enhances the motility and invasiveness of cancer cells.
    J Clin Invest. 2025;135:e180570.
    >> Share

    May 2025
  19. APPADURAI MI, Chaudhary S, Shah A, Natarajan G, et al
    ST6GalNAc-I regulates tumor cell sialylation via NECTIN2/MUC5AC-mediated immunosuppression and angiogenesis in non-small cell lung cancer.
    J Clin Invest. 2025;135:e186863.
    >> Share

    April 2025
  20. O'KEEFE S, Wang Q
    ACAT1 regulates tertiary lymphoid structures: A target for enhancing immunotherapy in non-small cell lung cancer.
    J Clin Invest. 2025;135:e191094.
    >> Share

  21. WANG S, Guo H, Fukushima R, Terajima M, et al
    Lysyl hydroxylase 2 glucosylates collagen VI to drive lung cancer progression.
    J Clin Invest. 2025;135:e189197.
    >> Share

  22. JIAO M, Guo Y, Zhang H, Wen H, et al
    ACAT1 regulates tertiary lymphoid structures and correlates with immunotherapy response in non-small cell lung cancer.
    J Clin Invest. 2025;135:e181517.
    >> Share

    March 2025
  23. SHEN S, Zhang Q, Wang Y, Chen H, et al
    Targeting ubiquitin-independent proteasome with small molecule increases susceptibility in pan-KRAS-mutant cancer models.
    J Clin Invest. 2025;135:e185278.
    >> Share

    February 2025
  24. YU F, Zheng S, Yu C, Gao S, et al
    KRAS Mutants Confer Platinum Resistance by Regulating ALKBH5 Post-translational Modifications in Lung Cancer.
    J Clin Invest. 2025 Feb 4:e185149. doi: 10.1172/JCI185149.
    >> Share

    December 2024
  25. LI D, Geng K, Hao Y, Gu J, et al
    Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models.
    J Clin Invest. 2024 Dec 24:e174249. doi: 10.1172/JCI174249.
    >> Share

    October 2024
  26. HUANG Q, Tian N, Zhang J, Song S, et al
    Nonclassical action of Ku70 promotes Treg-suppressive function through a FOXP3-dependent mechanism in lung adenocarcinoma.
    J Clin Invest. 2024;134:e178079.
    >> Share

    September 2024
  27. REEVES MQ
    Mapping the transcriptional evolution of human metastatic breast cancer.
    J Clin Invest. 2024;134:e183971.
    >> Share

    June 2024
  28. PARDO L, Norman JC
    Targeting the secretory program of 3q-amplified lung cancers.
    J Clin Invest. 2024;134:e181798.
    >> Share

    May 2024
  29. MILLS GB, Labrie M
    Enhancing anticancer activity of macrophages through rational drug combinations.
    J Clin Invest. 2024;134:e180512.
    >> Share

    April 2024
  30. HAYASHI H, Chamoto K, Hatae R, Kurosaki T, et al
    Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
    J Clin Invest. 2024;134:e168318.
    >> Share

  31. TAN AC, Cook SL, Khasraw M
    Soluble immune-checkpoint factors: a potential immunotherapy biomarker.
    J Clin Invest. 2024;134:e179352.
    >> Share

    March 2024
  32. VACCARO K, Allen J, Whitfield TW, Maoz A, et al
    Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.
    J Clin Invest. 2024;134:e169315.
    >> Share

  33. CHEN Z, Vallega KA, Wang D, Quan Z, et al
    DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
    J Clin Invest. 2024 Mar 7:e172716. doi: 10.1172/JCI172716.
    >> Share

    January 2024
  34. PEYVANDI S, Bulliard M, Yilmaz A, Kauzlaric A, et al
    Tumor-educated Gr1+CD11b+ cells drive breast cancer metastasis via OSM/IL6-JAK-induced cancer cell plasticity.
    J Clin Invest. 2024 Jan 18:e166847. doi: 10.1172/JCI166847.
    >> Share

  35. GHANBAR MI, Suresh K
    Pulmonary toxicity of immune checkpoint immunotherapy.
    J Clin Invest. 2024;134:e170503.
    >> Share

    December 2023
  36. JING N, Zhang K, Chen X, Liu K, et al
    ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers.
    J Clin Invest. 2023;133:e168670.
    >> Share

  37. WANG S, Iyer R, Han X, Wei J, et al
    CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion.
    J Clin Invest. 2023;133:e167728.
    >> Share

    November 2023
  38. MAKINEN N, Meyerson M
    Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer.
    J Clin Invest. 2023;133:e174171.
    >> Share

    October 2023
  39. LIU S, Saunders M, Mak TW
    Chemical carcinogens: implications for cancer treatment.
    J Clin Invest. 2023;133:e174319.
    >> Share

  40. HUANG M, Xia Y, Li K, Shao F, et al
    Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment.
    J Clin Invest. 2023;133:e166494.
    >> Share

  41. WANG T, Dong Y, Huang Z, Zhang G, et al
    Antioxidants stimulate BACH1-dependent tumor angiogenesis.
    J Clin Invest. 2023;133:e169671.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016